Clonal evolution and mechanisms of acquired resistance to CDK4/6 inhibitors in ER-wild type and ER-mutant breast cancer

被引：4
|
作者：
Guarducci, Cristina
Cristea, Simona
Feit, Avery
Naumenko, Sergey
Nardone, Agostina
Ma, Wen
Russo, Douglas
Feit, Gabriella Cohen
Feiglin, Ariel
Hermida-Prado, Francisco
Sherman, Shira
Brown, Myles
Michor, Franziska
Jeselsohn, Rinath
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-GS3-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS3-07
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors in ER plus breast cancer
    Sudhan, Dhivya R.
    Chatterjee, Sumanta
    Kim, Jiwoong
    Wang, Yunguan
    Kandagatla, Vishal
    Ye, Dan
    Lin, Chang-Ching
    Zanudo, Jorge Gomez Tejeda
    Jain, Esha
    Marin, Arnaldo
    Servetto, Alberto
    Lee, Kyung-min
    Povedano, Juan Manuel
    McFadden, David
    Barrett, Alex
    Wagle, Nikhil
    Hanker, Ariella B.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2022, 82 (04)
  • [32] 6-Phosphofructo-2-kinase inhibition to increase the efficacy of ER and CDK4/6 inhibitors against ER plus breast cancer
    Lanceta, Lilibeth
    Lypova, Nadiia
    Chesney, Jasson
    Imbert-Fernandez, Yoannis
    CANCER RESEARCH, 2020, 80 (16)
  • [33] Loss of mismatch repair predicts resistance to endocrine therapy and sensitivity to CDK4/6 inhibitors in ER+ breast cancer
    Haricharan, Svasti
    Punturi, Nindo
    Singh, Purba
    Holloway, Kimberly R.
    Anurag, Meenakshi
    Schmelz, Jacob
    Schmidt, Cheryl
    Lei, Jonathan T.
    Suman, Vera
    Hunt, Kelly
    Olson, John A., Jr.
    Hoog, Jeremy
    Li, Shunqiang
    Huang, Shixia
    Edwards, Dean P.
    Kavuri, Shyam M.
    Bainbridge, Matthew N.
    Ma, Cynthia X.
    Ellis, Matthew J.
    CANCER RESEARCH, 2018, 78 (04)
  • [34] CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer
    Shi, Qiangfeng
    Yang, Wang
    Ouyang, Yiye
    Liu, Yujie
    Cai, Zijie
    BREAST CANCER RESEARCH, 2025, 27 (01)
  • [35] EGFR signaling as a mechanism of resistance to CDK4/6 inhibitors in Palbociclib-resistant ER plus breast cancer cells
    Lypova, Nadiia
    Lanceta, Lilibeth
    Dougherty, Susan M.
    Chesney, Jason A.
    Imbert-Fernandez, Yoannis
    CANCER RESEARCH, 2022, 82 (12)
  • [36] CDK 4/6 Inhibitors: Evolution and Revolution in the Management of ER plus Metastatic Breast Cancer
    Reddy, Priyanka M.
    Martin, James M.
    Montero, Alberto J.
    JCO ONCOLOGY PRACTICE, 2022, 18 (05) : 329 - +
  • [37] High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER plus breast cancer
    De Angelis, Carmine
    Fu, Xiaoyong
    Cataldo, Maria Letizia
    Nardone, Agostina
    Jansen, Valerie M.
    Veeraraghavan, Jamunarani
    Nanda, Sarmistha
    Qin, Lanfang
    Sethunath, Vidyalakshmi
    Pereira, Resel
    Benelli, Matteo
    Migliaccio, Ilenia
    Malorni, Luca
    Donaldson, Joshua
    Selenica, Pier
    Brown, David N.
    Weigelt, Britta
    Reis-Filho, Jorge S.
    Park, Ben H.
    Hurvitz, Sara A.
    Slamon, Dennis J.
    Rimawi, Mothaffar F.
    Jeselsohn, Rinath
    Osborne, Kent
    Schiff, Rachel
    CANCER RESEARCH, 2020, 80 (04)
  • [38] Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER plus breast cancer
    Mavrommati, Ioanna
    Moughari, Fatemeh Ahmadi
    Thakur, Shefali
    Zhang, Yu
    Martin, Lesley-Ann
    Haider, Syed
    Natrajan, Rachael
    CANCER RESEARCH, 2024, 84 (03)
  • [39] Molecular profiling of ER plus metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors.
    Razavi, Pedram
    dos Anjos, Carlos Henrique
    Brown, David N.
    Qing, Li
    Ping, Christina
    Herbert, Joshua
    Colon, Jodecy
    Liu, Dazhi
    Mao, Maiya
    Norton, Larry
    Scaltriti, Maurizio
    Solit, David B.
    Robson, Mark E.
    Reis-Filho, Jorge S.
    Jhaveri, Komal L.
    Chandarlapaty, Sarat
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] CDK4/6 inhibitors in breast cancer
    Dukelow, Tim
    Kishan, Divya
    Khasraw, Mustafa
    Murphy, Conleth G.
    ANTI-CANCER DRUGS, 2015, 26 (08) : 797 - 806
12345